[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organ-preservation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organ-preservation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,95,124,151,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100289723","phase-2-randomizing-two-radiotherapy-boost-options-to-avoid-rectal-cancer-surgery-100289723",false,"NCT03051464","Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer","MORPHEUS","Inclusion Criteria:\n\n* Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic\u002Ftrans-rectal ultrasound\n* Rectal cancer staged as N0-1 by MRI or EUS\u002FTRUS\n* No metastatic lesion\n* Rectal tumor occupying less than half of the circumference\n* Tumor less than 5 cm on its largest dimension\n* Tumor located at less than 10 cm from the anal verge\n* Tumor penetration less than 5 mm in the mesorectal fat\n* Tumor accessible for brachytherapy\n* Lumen accessible for colonoscopy\n* Patient should be a suitable candidate for brachytherapy and chemotherapy\n* Older than 18 years of age\n* Adequate birth control measures in women of childbearing potential\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with previous pelvic radiation\n* Evidence of distant metastasis\n* Extension of malignant disease to the anal canal\n* Tumors staged as T4\n* Tumors larger than 5 cm in length","ALL","18 Years","80 Years",{"count":21,"type":22},131,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).",[29,30,31,32,33],"Stage II Rectal Cancer","Organ Preservation","Non-operative Treatment","Rectal Cancer (Stage III)","Rectal Cancer Patients",[35,36,37,38,39,40,41,42],"rectal cancer","non-operative management","rectal preservation","organ preservation","brachytherapy boost for rectal cancer","low rectal cancer curative treatment","mid rectal cancer curative treatment","rectal brachytherapy","RECRUITING","2026-06-25",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":47},"2017-04-25",{"date":51,"type":22},"2030-01",{"name":53,"class":54},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",4,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":78,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":64,"type":22},400,[25,26],"This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[68,69,70,71,72,30,73,74,75,76,77],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Chemotherapy","Radiotherapy Side Effect","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[79,69,80,71,72,75,30,73,81,82,83,84,76],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","2026-05-06",{"date":87,"type":47},"2026-05-11",{"date":89,"type":47},"2025-01-06",{"date":91,"type":22},"2029-12-27",{"name":93,"class":54},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":94},"100636301","total-neoadjuvant-therapy-with-additional-consolidation-chemotherapy-followed-by-local-excision-versus-total-neoadjuvant-therapy-followed-by-local-excision-at-stage-i-rectal-cancer-100636301","NCT07563907","Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer","Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial","OPTION","Inclusion Criteria:\n\n* Histologically confirmed rectall adenocarcinoma\n* Low rectal cancer (AV \\\u003C 15cm)\n* cT2N0 disease, or pathologic stage T1N0 disease after endoscopic resection with at least one high-risk feature, including: Positive resection margin Lymphovascular invasion Tumor budding ≥5\n* Ability to understand and comply with the requirements of the clinical trial\n\nExclusion Criteria:\n\n* Patients who prefer radical rectal resection\n* Prior history of surgery for rectal cancer\n* Recurrent rectal cancer\n* Synchronous metastatic rectal cancer\n* Evidence of lymph node metastasis or distant metastasis on abdominopelvic CT or chest CT, including para-aortic, common iliac, or external iliac lymph node metastasis\n* Uncontrolled active infection or other uncontrolled medical condition\n* Known hypersensitivity to chemotherapy\n* Patients considered unsuitable for participation in the clinical trial by the principal investigator or study personnel","19 Years","79 Years",{"count":106,"type":22},292,[108],"NA","Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial\n\nThe goal of this clinical trial is to find out if adding consolidation chemotherapy with capecitabine after total neoadjuvant chemoradiotherapy (TNT) works to improve oncologic outcomes in patients with stage I rectal cancer. It will also comparethe safety of adding consolidation chemotherapy before local excision.\n\nThe main questions it aims to answer are:\n\n* Does adding consolidation chemotherapy increase the rate of pathologic complete response?\n* What medical problems or side effects do participants have during and after treatment?\n\nResearchers will compare TNT followed by local excision to TNT followed by consolidation chemotherapy with capecitabine and then local excision to see if adding consolidation chemotherapy improves tumor response and treatment outcomes.\n\nParticipants will:\n\n* Receive TNT for stage I rectal cancer\n* Be randomly assigned to one of two treatment groups\n* Undergo local excision after preoperative treatment\n* Visit the clinic for checkups and tests to evaluate tumor response, side effects, recurrence, survival, quality of life, bowel function, urinary function, sexual function, circulating tumor DNA, and treatment-related costs",[30,111,69,112,113],"Rectal Cancer Stage I","Consolidation Therapy","Capecitabine","NOT_YET_RECRUITING","2026-04-26",{"date":117,"type":47},"2026-05-04",{"date":119,"type":22},"2026-06-01",{"date":121,"type":22},"2035-12-31",{"name":123,"class":54},"Seoul National University Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":94},"100625538","multimodal-neuromonitoring-during-normothermic-regional-perfusion-for-organ-donors-determined-dead-by-circulatory-criteria-following-withdrawal-of-life-sustaining-measures-100625538","NCT07423936","Multimodal Neuromonitoring During Normothermic Regional Perfusion for Organ Donors Determined Dead by circuLatory Criteria Following Withdrawal of Life Sustaining Measures","Multimodal NeurOmonitoring During NormOthermic Regional PerFusion for Organ Donors Determined Dead by CircuLatory Criteria fOllowing Withdrawal of Life Sustaining Measures (NONOFLOW): A Proof-of-Concept Study","NONOFLOW","Inclusion Criteria:\n\n1. Age \\> 18;\n2. Planned DCD within the next 96 hours.\n\nExclusion Criteria:\n\n1. Coagulopathy (International normalized ratio \\> 1.5, prothrombin time \\> 45 seconds, platelets \\\u003C 50);\n2. Therapeutic anticoagulant medication administration.",{"count":133,"type":22},30,"OBSERVATIONAL","The aim of this study is to demonstrate that cerebral blood flow and brain function do not resume after death declaration in organ donors who undergo normothermic regional perfusion to restore organ function following death determination by circulatory criteria, when appropriate safeguards are applied.\n\nTo assess the absence of cerebral perfusion and function, investigators will use continuous and comprehensive multimodal neuromonitoring throughout the withdrawal of life-sustaining therapies, the dying process and the NRP procedure.",[30,137],"Brain Reperfusion or Regain of Brain Function During Normothermic Regional Perfusion",[139,140,141],"Normothermic regional perfusion","donation after cardiac death","organ donation","2026-02-13",{"date":144,"type":47},"2026-02-20",{"date":146,"type":47},"2025-02-24",{"date":148,"type":22},"2028-12",{"name":150,"class":54},"University of British Columbia",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100619765","predictive-accuracy-of-machine-perfusion-for-kidney-transplant-outcomes-in-germany-100619765","NCT07348874","Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany","Predictive Accuracy of Machine Perfusion Parameters for Kidney Allograft Outcome - A National Analysis Following the Commencement of Hypothermic Machine Preservation of Extended Criteria Donor (ECD) Kidneys in Germany","PRE-MAP-Kidney","Inclusion Criteria:\n\n1. Signed informed consent\n2. Patients 18 years or older\n3. Listed for kidney transplantation (KT)\n4. Receiving ECD\\* donation after brain death kidney allografts following national organ procurement\n5. Kidney allograft being transported at continuous HMP\n6. Transplantation of recipient at a national transplant center\n\n   * Extended Criteria Donation:\n\n1\\. Donor age ≥ 60 years 2. Donor age 50 - 59 plus 2 additional attributes: I. Arterial hypertension in medical history II. Last serum creatinine \\>1.5mg\u002FdL (133mmol\u002FL) III. Cerebrovascular cause of death\n\nExclusion Criteria:\n\n1. Recipients of living donor KT\n2. Combined transplantations (liver-kidney, kidney-pancreas, etc.)\n3. Participation in another intervention-trial with interference of intervention and\u002For outcome of this study\n4. Unwilling or unable to follow the procedures outlined in the protocol\n5. Mentally or legally incapacitated\n6. Inability to understand the procedures due to language barriers",{"count":160,"type":22},300,"Kidney transplantation remains the only definitive treatment for end-stage renal disease, yet the increasing use of extended criteria donor (ECD) kidneys heightens the risk of ischemia-reperfusion injury, particularly under static cold storage (SCS). Continuous hypothermic machine perfusion (HMP) has been introduced to improve preservation quality, but robust clinical evidence regarding its predictive value for post-transplant outcomes in ECD kidneys after donation after brain death (DBD) is limited.\n\nThe PRE-MAP Kidney Study is a prospective, non-interventional, multicenter observational study conducted across all German transplant centers. The study systematically collects technical machine perfusion parameters (flow, resistance, perfusion duration) and correlates these with clinical outcomes following kidney transplantation.\n\nThe primary endpoint is 12-month kidney function (eGFR). Secondary endpoints include surgical complications, length of stay, and transplant-specific events (acute rejection, primary non-function, delayed graft function).\n\nThis national cohort aims to determine the prognostic significance of HMP parameters in marginal donor kidneys and to generate evidence supporting future recommendations for organ preservation and allocation practices.",[163,164,30],"Kidney Transplant","Renal Transplant",[166,167,168,169,30,170],"Machine Perfusion","Hypothermic Machine Perfusion","Upfront Machine Perfusion","Continuous Machine Perfusion","Marginal Allograft","2026-01-09",{"date":173,"type":47},"2026-01-16",{"date":175,"type":22},"2026-01-19",{"date":177,"type":22},"2028-02-01",{"name":179,"class":54},"University Hospital Heidelberg",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":94},"100591590","zeroheart-biopsy---prediction-of-deceased-donor-heart-transplant-performance-from-organ-donors-using-pre-transplant-biopsies---a-pilot-study-100591590","NCT06982404","ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study","ZeroHeart","Inclusion Criteria:\n\nAll hearts from standard and expanded criteria donors as well as donor hearts from Donation after circulatory death (DCD) undergoing a heart biopsy at pre-implantation (at procurement) will be included. Consent will be obtained from the recipient at the time of transplant listing.\n\nExclusion Criteria:\n\nHearts will be excluded from the study if the participating clinician decides to discard the organ before transplantation or the recipient declines that the biopsy will be performed at the organ procurement.",{"count":188,"type":22},50,"The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal (\"Time Zero\") can help predict the future function and rejection risk of the transplanted heart in adult transplant recipients.\n\nThe main questions it aims to answer are:\n\n* Can early molecular injury in the donor heart, caused by brain death or circulatory death, be detected at the time of organ removal?\n* Can these early molecular findings predict short-, mid-, and long-term transplant outcomes, such as graft function or rejection?\n\nParticipants will:\n\n* Include heart donors whose hearts are being transplanted (both standard and marginal donors, including DBD and DCD cases)\n* Provide two small biopsies from the donor heart at the time of organ removal: one for routine pathology, one for microarray-based molecular analysis\n* Have routine follow-up biopsies after transplantation as part of standard care (no additional procedures required beyond medical standard)\n\nResearchers will compare biopsy results from different donor types (standard vs. marginal, DBD vs. DCD) to see if early molecular signals are linked to later heart transplant outcomes.",[191,192,193,30,194,195],"Heart Transplantation","Graft Rejection","Myocardial Injury","Biopsy","Gene Expression Profiling","2025-05-13",{"date":198,"type":47},"2025-05-21",{"date":200,"type":47},"2025-05-12",{"date":202,"type":22},"2028-05-31",{"name":204,"class":54},"Medical University of Vienna",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":5},"100498643","organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision-100498643","NCT05772923","Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision","Organ Preservation in Patients With a Good Clinical Response After (Chemo)Radiation for Rectal Cancer: Defining the Role of Additional Contact X-ray Brachytherapy Versus Extending the Waiting Interval and Local Excision","OPAXX","Inclusion Criteria:\n\n* histologically verified adenocarcinoma above the dentate line and within 10cm of the anal verge;\n* neoadjuvant short-course radiotherapy for patients with 1) IRC and delayed response evaluation according to the Dutch national guidelines (cT1-3, cN1-2 lymph nodal status, no involved MRF or cT3c-d, N0-1 lymph nodal status without pres-ence of significant distant metastases) without full dose chemotherapy in the inter-val (e.g. Rapido-scheme) or 2) LARC due to comorbidity or frailty; OR\n* neoadjuvant long-course radiotherapy (chemoradiation) for patients with 1) LARC according to the Dutch national guidelines (cT4 tumour, cN2 lymph nodal status, lateral lymph node involvement, and\u002For involved MRF, without the presence of significant distant metastases) or 2) early rectal cancer or IRC and a strong wish for organ preservation;\n* clinically near-complete response or a small residual tumour mass \\\u003C3 cm;\n* technically feasible to perform both treatment options (contact x-ray brachytherapy or local excision);\n* age \\>18 years;\n* written informed consent.\n\nExclusion Criteria:\n\n* neoadjuvant or induction chemotherapy prior or adjacent to (chemo)radiation, e.g. patients with a Rapido or M1-scheme are not eligible;\n* radiation dose \\>50.4 Gy or boost dose on the primary tumour;\n* presence of suspicious lymph nodes (yN1\u002FN2) at first response evaluation;\n* residual tumour ≥ 3cm or over half of the circumference of the rectal lumen;\n* patients who are unable to undergo contact x-ray brachytherapy or local excision;\n* patients who cannot tolerate a completion- or salvage-TME because of comorbidity or frailty;",{"count":214,"type":22},168,[108],"The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy versus extension of the waiting interval with or without local excision, and to investigate which rate of organ preservation can be achieved.",[30,68,77,218],"Locally Advanced Rectal Carcinoma",[220,79,221,222,223,224],"Organ preservation","(Chemo)radiation","Local excision","Contact x-ray brachytherapy","TAMIS","2023-03-14",{"date":227,"type":47},"2023-03-17",{"date":229,"type":47},"2021-04-16",{"date":231,"type":22},"2029-03",{"name":233,"class":54},"The Netherlands Cancer Institute"]